Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications

Fig. 2

In vivo analysis of combined ATR (AZD6738) and ATM (AZD0156) inhibition in two STS models: (A) in IB115 cell line xenograft after 3 weeks of treatment and (B) in PDX model JR588. After 3 weeks of treatment, tumour volume was measured 10 days after the end of treatment. In vitro, there is a synergistic effect with the two drugs for IB115 and JR588 (data not shown) (C) yH2AX IHC analysis in PDX model for vehicle, each drug used as single agent or in combination. (D) The graph represent the two values of IHC score. Slides were digitalized at 20X on a PhenoImager HT (Akoya) and tissues were analyzed using Inform software v2.6 (Akoya), an IHC score for yH2AX positivity (2-bin) was defined based a 0.25 positivity threshold for each condition

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us